

Financial news for KPTI dated on 2020-06-09: Karyopharm Therapeutics Reports Dosing Of First Patient In Phase 1/2 Study Of Selinexor In Combo With Standard Of Care Therapy For Patients With Newly Diagnosed, Recurrent Glioblastoma

Financial news for KPTI dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for KPTI dated on 2020-05-29: 20 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for KPTI dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for KPTI dated on 2020-05-28: Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Financial news for KPTI dated on 2020-05-20: Karyopharm Therapeutics shares are trading higher after the company reported the submission of a supplemental New Drug Application to the FDA seeking approval for XPOVIO.

Financial news for KPTI dated on 2020-05-20: Karyopharm Therapeutics Reports Submission Of Supplemental New Drug Application For XPOVIO As Treatment For Patients With Multiple Myeloma After At Least One Prior Line Of Therapy

Financial news for KPTI dated on 2020-05-06: HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to \$40

Financial news for KPTI dated on 2020-05-05: SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to \$29

Financial news for KPTI dated on 2020-05-05: Antengene Reports Broadened Partnership, Territory Expansion Deal With Karyopharm For Development, Commercialization Of 4 Oral Novel Drugs, Candidates

Financial news for KPTI dated on 2020-05-05: Recap: Karyopharm Therapeutics Q1 Earnings

Financial news for KPTI dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for KPTI dated on 2020-05-05: Karyopharm Therapeutics Q1 EPS \$(0.780) Misses \$(0.690) Estimate, Sales \$18.138M Miss \$21.280M Estimate

Financial news for KPTI dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for KPTI dated on 2020-04-20: Karyopharm Announces Dosing Of First Patient In Randomized Study Evaluating Low Dose Selinexor In Patients With Severe Coronavirus (COVID-19)

Financial news for KPTI dated on 2020-04-08: Komodo Health Reports Partnership With Karyopharm To Accelerate Global Clinical Trial To Treat Patients With Coronavirus

Financial news for KPTI dated on 2020-04-07: Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with Coronavirus

Financial news for KPTI dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for KPTI dated on 2020-03-12: Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer

Financial news for KPTI dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for KPTI dated on 2020-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2020

Financial news for KPTI dated on 2020-03-04: 36 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for KPTI dated on 2020-03-04: Karyopharm Therapeutics Prices 6.25M Share Public Offering of Common Stock @\$24/Share

Financial news for KPTI dated on 2020-03-04: Barclays Initiates Coverage On Karyopharm Therapeutics with Overweight Rating, Announces \$30 Price Target

Financial news for KPTI dated on 2020-03-04: 85 Biggest Movers From Yesterday

Financial news for KPTI dated on 2020-03-03: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KPTI dated on 2020-03-03: Karyopharm Therapeutics shares are trading lower after the company announced a proposed public offering of common stock of \$150 million.

Financial news for KPTI dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for KPTI dated on 2020-03-03: 40 Stocks Moving in Tuesday's Pre-Market Session

Financial news for KPTI dated on 2020-03-03: 108 Biggest Movers From Yesterday

Financial news for KPTI dated on 2020-03-02: 15 Stocks Moving In Monday's After-Hours Session

Financial news for KPTI dated on 2020-03-02: Karyopharm Therapeutics shares are trading lower after the company announced a proposed public offering of common stock of \$150 million.

Financial news for KPTI dated on 2020-03-02: Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock Of \$150 Million In Shares Of Common Stock

Financial news for KPTI dated on 2020-03-02: HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to \$43

Financial news for KPTI dated on 2020-03-02: 55 Stocks Moving In Monday's Mid-Day Session

Financial news for KPTI dated on 2020-03-02: 30 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2020-03-02: Karyopharm Therapeutics shares are trading higher after the company announced its Phase 3 BOSTON study met its primary endpoint with significant increase in progression-free survival in patients with multiple myeloma.

Financial news for KPTI dated on 2020-03-02: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for KPTI dated on 2020-03-02: Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy

Financial news for KPTI dated on 2020-02-26: Karyopharm Therapeutics Filing Shows Registration For Mixed Securities Offering, No Size Disclosed

Financial news for KPTI dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for KPTI dated on 2020-02-19: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for KPTI dated on 2020-02-19: FDA Accepts Karyopharm's Supplemental New Drug Application For XPOVIO As A Treatment For Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Financial news for KPTI dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for KPTI dated on 2020-02-13: Karyopharm Therapeutics Q4 EPS \$(0.76) Misses \$(0.67) Estimate, Sales \$17.7M Beat \$16.34M Estimate

Financial news for KPTI dated on 2020-02-11: Karyopharm And Promedico Enter Into Exclusive Distribution Agreement To Commercialize XPOVIO In Israel

Financial news for KPTI dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for KPTI dated on 2020-02-03: Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for KPTI dated on 2020-01-21: Benzinga's Top Upgrades, Downgrades For January 21, 2020

Financial news for KPTI dated on 2020-01-21: 60 Biggest Movers From Friday

Financial news for KPTI dated on 2020-01-17: Benzinga's Top Upgrades, Downgrades For January 17, 2020

Financial news for KPTI dated on 2020-01-17: Wedbush Downgrades Karyopharm Therapeutics to Neutral

Financial news for KPTI dated on 2020-01-14: H.C. Wainwright Reiterates Buy on Karyopharm Therapeutics, Raises Price Target to \$37

Financial news for KPTI dated on 2020-01-13: Karyopharm Sees Prelim. Q4 XPOVIO Sales \$17M-\$18M, Prelim. FY19 XPOVIO Sales \$30M-\$31M

Financial news for KPTI dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for KPTI dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for KPTI dated on 2020-01-09: Karyopharm Therapeutics shares are trading higher on seemingly no company-specific news to justify the price action.

Financial news for KPTI dated on 2020-01-03: Benzinga's Top Upgrades, Downgrades For January 3, 2020

Financial news for KPTI dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for KPTI dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for KPTI dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for KPTI dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for KPTI dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for KPTI dated on 2019-12-23: Karyopharm Submits New Drug Application to the FDA for XPOVIO as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Financial news for KPTI dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2019-12-09: There's A Really Good Chance You Missed One Of The Year's Best ETFs

Financial news for KPTI dated on 2019-12-08: Karyopharm Presents Four Posters Relating to XPOVIO at ASH 2019

Financial news for KPTI dated on 2019-12-07: Karyopharm Reports New and Updated XPOVIO Data in Relapsed or Refractory Multiple Myeloma at ASH 2019

Financial news for KPTI dated on 2019-12-06: Karyopharm Therapeutics shares are trading lower on seemingly no company-specific news.

Financial news for KPTI dated on 2019-12-02: Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule

Financial news for KPTI dated on 2019-11-29: Stocks That Hit 52-Week Highs On Friday

Financial news for KPTI dated on 2019-11-29: Karyopharm Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for KPTI dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for KPTI dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for KPTI dated on 2019-11-22: Stocks That Hit 52-Week Highs On Friday

Financial news for KPTI dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for KPTI dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for KPTI dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for KPTI dated on 2019-11-18: Stocks That Hit 52-Week Highs On Monday

Financial news for KPTI dated on 2019-11-15: Stocks That Hit 52-Week Highs On Friday

Financial news for KPTI dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for KPTI dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for KPTI dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for KPTI dated on 2019-11-08: Stocks That Hit 52-Week Highs On Friday

Financial news for KPTI dated on 2019-11-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for KPTI dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for KPTI dated on 2019-11-05: UPDATE: H.C. Wainwright Maintains Buy On Karyopharm Therapeutics, Raises Target To \$36 Notes 'Xpovio Launch Starts Strong'; 'Topline BOSTON data expected early 2020', 'NDA submission is expected in 2020 if the BOSTON data are positive'

Financial news for KPTI dated on 2019-11-05: Karyopharm Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. Following earnings, multiple firms maintained Buy ratings on the stock and raised the price target.

Financial news for KPTI dated on 2019-11-05: Canaccord Genuity Maintains Buy on Karyopharm Therapeutics, Raises Price Target to \$18

Financial news for KPTI dated on 2019-11-05: H.C. Wainwright Maintains Buy on Karyopharm Therapeutics, Raises Price Target to \$36

Financial news for KPTI dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for KPTI dated on 2019-11-04: Stocks That Hit 52-Week Highs On Monday

Financial news for KPTI dated on 2019-11-04: Karyopharm Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for KPTI dated on 2019-11-04: 24 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2019-11-04: Karyopharm Therapeutics Q3 EPS \$(0.67) Beats \$(0.84) Estimate, Sales \$13.149M Beat \$1.8M Estimate

Financial news for KPTI dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for KPTI dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for KPTI dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for KPTI dated on 2019-09-23: Karyopharm Therapeutics shares trading lower for the third day in a row following a failed test of a resistance level at

\$12. After rallying for nine straight sessions, shares fell below the \$11 level on Friday of last week and are below the \$10 level today.

Financial news for KPTI dated on 2019-09-16: 22 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2019-09-16: Karyopharma Reports Royalty Deal With Healthcare Royalty Partners For Up To \$150M

Financial news for KPTI dated on 2019-09-06: 25 Stocks Moving in Friday's Pre-Market Session

Financial news for KPTI dated on 2019-09-06: 86 Biggest Movers From Yesterday

Financial news for KPTI dated on 2019-08-22: 12 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for KPTI dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for KPTI dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for KPTI dated on 2019-08-06: Karyopharm Therapeutics Q2 EPS \$(0.41) May Not Compare To \$(0.98) Estimate, Sales \$9.493M Beat \$90K Estimate

Financial news for KPTI dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for KPTI dated on 2019-07-31: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Financial news for KPTI dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for KPTI dated on 2019-07-24: 60 Biggest Movers From Yesterday

Financial news for KPTI dated on 2019-07-23: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KPTI dated on 2019-07-23: Benzinga's Top Upgrades, Downgrades For July 23, 2019

Financial news for KPTI dated on 2019-07-23: 10 Biggest Price Target Changes For Tuesday

Financial news for KPTI dated on 2019-07-23: Karyopharm Therapeutics shares are trading higher after JP Morgan upgraded the company from Neutral to Overweight and raised the price target from \$8 to \$16.

Financial news for KPTI dated on 2019-07-23: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KPTI dated on 2019-07-23: JP Morgan Upgrades Karyopharm Therapeutics to Overweight, Raises Price Target to \$16

Financial news for KPTI dated on 2019-07-11: Ivy Brain Tumor Center At Barrow Partners With Karyopharm Therapeutics To Accelerate Treatment Of Brain Cancer, No Terms Disclosed

Financial news for KPTI dated on 2019-07-09: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KPTI dated on 2019-07-05: Large Option Trader Dumps Karyopharm Puts Following Xpovio Approval Rally

Financial news for KPTI dated on 2019-07-05: HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval

Financial news for KPTI dated on 2019-07-05: 24 Stocks Moving In Friday's Mid-Day Session

Financial news for KPTI dated on 2019-07-05: Benzinga Pro's Top 7 Most-Searched Tickers For Morning of Friday., July 05, 2019

Financial news for KPTI dated on 2019-07-05: 5 Biggest Price Target Changes For Friday

Financial news for KPTI dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

Financial news for KPTI dated on 2019-07-05: 21 Stocks Moving In Friday's Pre-Market Session

Financial news for KPTI dated on 2019-07-05: A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report

Financial news for KPTI dated on 2019-07-05: Karyopharm Therapeutics shares are trading higher on continued strength after the company on Wednesday announced FDA approval of XPOVIO for treatment of patients with relapsed, refractory multiple myeloma.

Financial news for KPTI dated on 2019-07-05: Karyopharm Therapeutics Shares Rise 21% Premarket; Baird Raises Price Target to \$25 from \$15

Financial news for KPTI dated on 2019-07-05: 48 Biggest Movers From Wednesday

Financial news for KPTI dated on 2019-07-03: UPDATE: Karyopharm Shares Pullback From High But Still Up 31% For Session

Financial news for KPTI dated on 2019-07-03: Karyopharm Therapeutics Shares Resume Trade, Move Lower

Financial news for KPTI dated on 2019-07-03: Karyopharm Therapeutics Shares To Resume Trade At 1:35 p.m. EDT

Financial news for KPTI dated on 2019-07-03: Karyopharma 8-K Shows Chief Commercial Officer Anand Varadan Resigned

Financial news for KPTI dated on 2019-07-03: Karyopharm Reports FDA Approval Of XPOVIO (selinexor) For Treatment Of Patients With Relapsed, Refractory Multiple Myeloma

Financial news for KPTI dated on 2019-07-03: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for KPTI dated on 2019-07-03: 'FDA approves new treatment for refractory multiple myeloma' -FDA Release On Karyopharm's Selinexor

Financial news for KPTI dated on 2019-07-03: Mid-Day Market Update: Dow Rises Over 150 Points; OMNOVA Solutions Shares Spike Higher

Financial news for KPTI dated on 2019-07-03: Karyopharm Spikes Higher After Selinexor Leak

Financial news for KPTI dated on 2019-07-03: Karyopharm Therapeutics shares trading higher following chatter the company's website for Selinexor went live.

Financial news for KPTI dated on 2019-07-03: Karyopharma Shares Halted News Pending

Financial news for KPTI dated on 2019-07-03: UPDATE On Karyopharm Upside: STAT News' Adam Feuerstein Recently Replied To Tweet, Saying '...I'm still seeing the website behind a firewall. Did someone "oops"?'

Financial news for KPTI dated on 2019-07-03: Upside In Karyopharm Shares Being Attributed To Unconfirmed Chatter Co.'s Selinexor Website Is Live, Word Of 'Apparent Accelerated Approval'

Financial news for KPTI dated on 2019-07-03: Karyopharm Therapeutics Shares Resume Trade, Up 14.5%

Financial news for KPTI dated on 2019-07-03: Karyopharm Therapeutics Shares Halted On Circuit Breaker, Up 8.4%

Financial news for KPTI dated on 2019-07-03: 44 Biggest Movers From Yesterday

Financial news for KPTI dated on 2019-07-01: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for KPTI dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for KPTI dated on 2019-06-19: Karyopharm Therapeutics Offers Updated Data From Phase 2b SADAL Study At International Conference on Malignant Lymphoma

Financial news for KPTI dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for KPTI dated on 2019-06-14: Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting

Financial news for KPTI dated on 2019-05-23: 55 Biggest Movers From Yesterday

Financial news for KPTI dated on 2019-05-21: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KPTI dated on 2019-05-16: Karyopharm Therapeutics Announces That Five Abstracts Relating To Selinexor Will Be Presented At The Upcoming European Hematology Association 2019 Annual Meeting Taking Place June 13-16, 2019 In Amsterdam

Financial news for KPTI dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for KPTI dated on 2019-05-09: Karyopharm Therapeutics Q1 EPS \$(1.09) Misses \$(0.87) Estimate

Financial news for KPTI dated on 2019-03-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for KPTI dated on 2019-03-19: 60 Biggest Movers From Yesterday

Financial news for KPTI dated on 2019-03-18: 75 Biggest Movers From Friday

Financial news for KPTI dated on 2019-03-15: 51 Stocks Moving In Friday's Mid-Day Session

Financial news for KPTI dated on 2019-03-15: FDA Delays Selinexor Approval By 3 Months -- So Why Is Karyopharm Ripping Higher?

Financial news for KPTI dated on 2019-03-15: Karyopharm shares are trading higher after the company announced FDA extension on the review period for its Selinexor New Drug Application.

Financial news for KPTI dated on 2019-03-15: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for KPTI dated on 2019-03-15: The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

Financial news for KPTI dated on 2019-03-14: Karyopharm shares are trading higher after the company announced FDA extension of the review period for its Selinexor New Drug Application.

Financial news for KPTI dated on 2019-03-14: Karyopharm Announces FDA Extension Of Review Period For Selinexor New Drug Application

Financial news for KPTI dated on 2019-03-01: The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis

Financial news for KPTI dated on 2019-03-01: JP Morgan Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to \$7

Financial news for KPTI dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for KPTI dated on 2019-02-28: Karyopharm Therapeutics Q4 EPS \$(0.96) Down From \$(0.80) YoY, Sales \$206K Down From \$1.534M YoY

Financial news for KPTI dated on 2019-02-28: 84 Biggest Movers From Yesterday

Financial news for KPTI dated on 2019-02-27: 72 Stocks Moving In Wednesday's Mid-Day Session

Financial news for KPTI dated on 2019-02-27: Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback

Financial news for KPTI dated on 2019-02-27: 10 Biggest Price Target Changes For Wednesday

Financial news for KPTI dated on 2019-02-27: Wedbush Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to \$6

Financial news for KPTI dated on 2019-02-27: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for KPTI dated on 2019-02-27: The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

Financial news for KPTI dated on 2019-02-27: Bank of America Downgrades Karyopharm Therapeutics to Underperform

Financial news for KPTI dated on 2019-02-26: UPDATE: Karyopharma Says 'we plan to work with the FDA to evaluate the best path forward as they continue to review our NDA'

Financial news for KPTI dated on 2019-02-26: Karyopharma Reports FDA AdCom Panel Reviewing Selinexor For Treatment Of Patients With Triple Class Refractory Multiple Myeloma Voted 8-5 Recommending FDA Wait For Results From Phase 3 BOSTON Study Before Making Final Decision Related To Approval

Financial news for KPTI dated on 2019-02-26: FDA Oncologic Drugs Advisory Committee Is Holding A Meeting Today From 12:30-5:00PM ET To Discuss Karyopharm's New Drug Application Requesting Accelerated Approval For Selinexor, A First-In-Class, Oral Selective Inhibitor Of Nuclear Export Comp

Financial news for KPTI dated on 2019-02-26: Karyopharm Shares Halted News Pending

Financial news for KPTI dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for KPTI dated on 2019-02-25: 'Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes' -STAT News

Financial news for KPTI dated on 2019-02-25: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2019-02-25: Karyopharm Announces Michael Mason CFO

Financial news for KPTI dated on 2019-02-25: 71 Biggest Movers From Friday

Financial news for KPTI dated on 2019-02-22: Karyopharm Therapeutics Option Alert: Mar 15 \$10 Calls Sweep (38) near the Bid: 1018 @ \$0.253 vs 3696 OI; Earnings 3/14 Before Open [est] Ref=\$5.285

Financial news for KPTI dated on 2019-02-22: Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug

Financial news for KPTI dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for KPTI dated on 2019-02-22: Karyopharm Therapeutics shares are trading lower after the FDA AdCom panel for Elinexor showed the FDA staff is unclear whether the treatment provides a clinically meaningful benefit which outweighs risks.

Financial news for KPTI dated on 2019-02-22: Karyopharm Shares Resume Trade, Rebound From Lows, Down 37% For Session

Financial news for KPTI dated on 2019-02-22: UPDATE: FDA Briefing Doc For Karyopharm AdCom Panel On Selinexor Shows FDA Staff Is Unclear Whether Treatment Provides Clinically Meaningful Benefit Which Outweighs Risks

Financial news for KPTI dated on 2019-02-22: Karyopharm Shares Halted On Circuit Breaker, Down 16.5%

Financial news for KPTI dated on 2019-02-22: Karyopharm Shares Dip To Session Low, Now Down 12.5% As Traders Circulate FDA Briefing Doc For Co.'s Feb. 26, 2019 AdCom Panel Meeting On Selinexor

Financial news for KPTI dated on 2019-02-07: Karyopharm Reports FDA Panel To Review Selinexor For Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies On Feb. 26, 2019 At 12:30 p.m. EST

Financial news for KPTI dated on 2019-02-06: Karyopharm Therapeutics Option Alert: Mar 15 \$7.5 Puts Sweep (18) near the Bid: 675 @ \$0.401 vs 5 OI; Earnings 3/14 Before Open [est] Ref=\$9.0

Financial news for KPTI dated on 2019-01-08: Karyopharma Reports Submission Of Marketing Authorization Application To EMA For Selinexor As Treatment For Patients With Pentra-Refractory Multiple Myeloma

Financial news for KPTI dated on 2019-01-03: Bank of America Upgrades Karyopharm Therapeutics to Neutral

Financial news for KPTI dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for KPTI dated on 2018-12-03: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for KPTI dated on 2018-12-03: Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at ASH 2018

Financial news for KPTI dated on 2018-12-03: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2018-11-25: The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Financial news for KPTI dated on 2018-11-09: Wedbush Upgrades Karyopharm Therapeutics to Outperform

Financial news for KPTI dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for KPTI dated on 2018-11-08: Karyopharm Therapeutics Q3 EPS \$(0.79) Beats \$(0.89) Estimate, Sales \$239K Miss \$460K Estimate

Financial news for KPTI dated on 2018-11-07: Karyopharma Reports FDA Issued Fast Track Designation For Selinexor For Treatment Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

Financial news for KPTI dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for KPTI dated on 2018-10-26: Karyopharm Therapeutics Reports CFO, Treasurer, Mike Falvey, To Leave; Exec. Search Will Commence Immediately

Financial news for KPTI dated on 2018-10-11: 41 Biggest Movers From Yesterday

Financial news for KPTI dated on 2018-10-10: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for KPTI dated on 2018-10-08: FDA On Friday Accepted Karyopharm's New Drug Application For Selinexor And Granted Priority Review

Financial news for KPTI dated on 2018-09-14: The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

Financial news for KPTI dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for KPTI dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for KPTI dated on 2018-08-29: The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Financial news for KPTI dated on 2018-08-10: Form 4 Filing Late Thursday Showed Karyopharm Therapeutics 10% Owner Chione Ltd Sold a Total of 80.876K Shares at Avg. Prices Ranging From \$18.50-\$18.71

Financial news for KPTI dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmmed's Antibiotic Faces FDA Panel

Financial news for KPTI dated on 2018-08-07: Karyopharm Therapeutics Q2 EPS \$(0.60) Beats \$(0.81) Estimate, Sales \$19.891M Beat \$3.09M Estimate

Financial news for KPTI dated on 2018-08-06: Karyopharm Therapeutics Reports Completed Rolling Submission Of New Drug Application For Selinexor As Treatment For Patients With Penta-Refractory Multiple Myeloma

Financial news for KPTI dated on 2018-07-18: Karyopharm Initiates Rolling Submission of New Drug Application To FDA For Selinexor, Company Plans to Complete Submission During the Second Half of 2018

Financial news for KPTI dated on 2018-07-02: Karyopharm Therapeutics Filing Shows Registration For Mixed Securities Shelf Offering, Includes Maximum Offer Value

~\$151.5M For Secondary Offering

Financial news for KPTI dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for KPTI dated on 2018-06-15: UPDATE: Karyopharm On Updated Selinexor Phase 1b/2 STOMP Data: SPd All Oral Regimen Shows Strong Response Rates: 55% ORR in Pomalyst-Naive and Revlimid-Relapsed or -Refractory MM with PFS of 11.6 months; 50% ORR in the Overall Study Population

Financial news for KPTI dated on 2018-06-15: UPDATE: Karyopharm On Updated Selinexor Phase 1b/2 STOMP Data: 82% ORR in Patients with Heavily Pretreated Darzalex-Naive MM; 68% ORR in the Overall Study Population

Financial news for KPTI dated on 2018-06-15: Karyopharm Offers Updated Selinexor Phase 1b/@ STOMP Myeloma Data Showed 17.8-month PFS and 83% ORR in the BOSTON Multiple Myeloma (MM) Population; 63% ORR in the Overall Study Population

Financial news for KPTI dated on 2018-06-07: Karyopharma Therapeutics Earlier Issued 8-K Which Shows Slideshow For Corporate Presentation, Includes Expectation For FY18 Operating Cash Burn \$175M-\$185M

Financial news for KPTI dated on 2018-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for KPTI dated on 2018-05-25: 45 Biggest Movers From Yesterday

Financial news for KPTI dated on 2018-05-24: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for KPTI dated on 2018-05-24: Benzinga's Top Upgrades, Downgrades For May 24, 2018

Financial news for KPTI dated on 2018-05-24: The Market In 5 Minutes: GE, Tariffs, Summit, Jobless Claims And More

Financial news for KPTI dated on 2018-05-24: UPDATE: Karyopharm Will Receive \$12M Upfront, Eligible To Receive Up To \$150M In Future Milestones Plus Royalties

Financial news for KPTI dated on 2018-05-24: Karyopharm, Antengene Report Signing Of Exclusive License Deal To Develop, Commercialize Selinexor, Eltanexor, Verdinexor, KPT-9274 In China, Other Regions In Asia

Financial news for KPTI dated on 2018-05-24: Wedbush Downgrades Karyopharm Therapeutics to Neutral

Financial news for KPTI dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for KPTI dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for KPTI dated on 2018-05-10: Karyopharm Therapeutics Q1 EPS \$(0.78) Misses \$(0.62) Estimate, Sales \$10M Beat \$5.84M Estimate

Financial news for KPTI dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for KPTI dated on 2018-05-04: 12 Biggest Movers Of The Week: Snap, Tenet, Wayfair And More

Financial news for KPTI dated on 2018-05-03: Karyopharm Therapeutics Prices ~9.15M Share Offering of Common Stock @\$14.75/Share

Financial news for KPTI dated on 2018-05-02: 42 Biggest Movers From Yesterday

Financial news for KPTI dated on 2018-05-01: Karyopharm Therapeutics Announces \$125M Common Stock Offering

Financial news for KPTI dated on 2018-05-01: Benzinga Pro's Most-Searched Tickers For Afternoon Of May 1, 2018

Financial news for KPTI dated on 2018-05-01: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KPTI dated on 2018-05-01: 21 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KPTI dated on 2018-05-01: Benzinga Pro's 5 Stocks To Watch Today

Financial news for KPTI dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for KPTI dated on 2018-05-01: 36 Biggest Movers From Yesterday

Financial news for KPTI dated on 2018-04-30: Karyopharm Therapeutics Inc Shares Up 20.8% After Hours Following Positive Trial Data From STORM Study For Selinexor; Co. To Submit NDA For Selinexor For Penta-Refractory Multiple Myeloma During 2H'18

Financial news for KPTI dated on 2018-04-30: Karyopharm Shares Resume Trade, Now Up 26.2%

Financial news for KPTI dated on 2018-04-30: Karyopharm Shares To Resume Trade At 4:35 p.m. EDT

Financial news for KPTI dated on 2018-04-30: Karyopharm Says Plans To Submit NDA For Selinexor For Penta-Refractory Multiple Myeloma During 2H'18

Financial news for KPTI dated on 2018-04-30: UPDATE: Karyopharm Says, Related To Primary Objective Of STORM Study For Selinexor, Results Included 2 Complete Responses, 29 Partial Or Very Good Partial Responses

Financial news for KPTI dated on 2018-04-30: Karyopharm Reports Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma: Achieved 25.4% Overall Response Rate, Median Duration Response Of 4.4 Mos.

Financial news for KPTI dated on 2018-04-30: Karyopharma Shares Halted News Pending

Financial news for KPTI dated on 2018-04-30: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for KPTI dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for KPTI dated on 2018-04-11: 36 Biggest Movers From Yesterday

Financial news for KPTI dated on 2018-04-10: 25 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KPTI dated on 2018-04-10: Benzinga Pro's 5 Stocks To Watch Today

Financial news for KPTI dated on 2018-04-10: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KPTI dated on 2018-04-10: Karyopharm's Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma

Financial news for KPTI dated on 2018-03-15: Karyopharm Says Cash, Cash Equivalents, Investments Will Be Sufficient To Fund Operations Through At Least Q1'19

Financial news for KPTI dated on 2018-03-15: Karyopharm Therapeutics Reports Q4 EPS \$(0.80) vs \$(0.65) Est.

Financial news for KPTI dated on 2018-03-11: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for KPTI dated on 2018-03-02: RBC Raises Karyopharm Therapeutics Price Target From \$15 To \$22 As Firm Believes Co.'s Valuation Relative To Other Small-Cap Oncology Co.'s Doesn't Reflect selinexor's Market Opportunity

Financial news for KPTI dated on 2018-01-26: Karyopharm Therapeutics S-3 Shows Registration For \$250M Mixed Securities Shelf Offering

Financial news for KPTI dated on 2018-01-26: 44 Biggest Movers From Yesterday

Financial news for KPTI dated on 2018-01-25: Benzinga Pro's 4 Stocks To Watch Today

Financial news for KPTI dated on 2018-01-25: Biogen to Acquire Karyopharm's KPT-350 for \$10M Upfront an Up to An Additional \$207M in Milestones and Royalties

Financial news for KPTI dated on 2017-12-11: Karyopharm Earlier Reported Phase 1/2 Eltanexor Data At ASH: Showed Candidate Is Well Tolerated, Demonstrated Promising Activity

Financial news for KPTI dated on 2017-12-11: Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at #ASH2017

Financial news for KPTI dated on 2017-11-15: Benzinga's Top Upgrades, Downgrades For November 15, 2017

Financial news for KPTI dated on 2017-11-15: H.C. Wainwright Assumes Karyopharm Therapeutics at Buy, Announces price target \$23.00

Financial news for KPTI dated on 2017-11-06: 13G Filing From Point72 Asset Mgmt Reporting 7.3% Stake In Karyopharm Therapeutics

Financial news for KPTI dated on 2017-11-03: Seeing Notable Block Trade In Karyopharm, 2M Shares At \$10.80/Share

Financial news for KPTI dated on 2017-11-02: Karyopharm Reports Q3 EPS \$(0.65) vs. \$(0.65) Est., Sales \$0 vs. \$30K Est.

Financial news for KPTI dated on 2017-10-16: Benzinga's Option Alert Recap From October 16

Financial news for KPTI dated on 2017-10-16: Karyopharm Option Alert: May 18 \$12.5 Calls at the Bid: 500 @ \$2.15 vs 51 OI; Ref=\$11.3325

Financial news for KPTI dated on 2017-10-12: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for KPTI dated on 2017-10-12: Karyopharm, Ono Pharmaceutical Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan; Other Countries in Asia; Karyopharm to Receive \$22.5M Upfront Payment

Financial news for KPTI dated on 2017-09-20: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for KPTI dated on 2017-09-20: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for KPTI dated on 2017-09-20: Karyopharm Reports SEAL Study's Primary Endpoint Of Progression-Free Survival Showed Superiority Over Placebo, Demonstrating Hazard Ratio Of 0.60, Representing 40% Reduction In Risk Of Progression Or Death

Financial news for KPTI dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for KPTI dated on 2017-09-12: Karyopharm Names Michael Falvey CFO

Financial news for KPTI dated on 2017-09-08: UPDATE: Karyopharm Says 'Top-line Phase 1 KPT-9274 Data Show a Manageable Safety Profile and Early Signals of Anti-Tumor Activity'

Financial news for KPTI dated on 2017-09-08: Karyopharm Reports Presentation Of Selinexor, KPT-9274 Data: Showed 'Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers'

Financial news for KPTI dated on 2017-08-08: Karyopharm Q2 EPS \$(0.64) vs \$(0.65) Est., Sales \$3K vs \$120K Est.

Financial news for KPTI dated on 2017-07-10: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2017-06-23: UPDATE: Karyopharm Reports Objective Response Rate To 33.3% Overall, 35% In Patients With Double Or Triple Hit DLBCL

Financial news for KPTI dated on 2017-06-23: Karyopharm Therapeutics Reports Updated Phase 2b SADAL Data For Selinexor In Diffuse Large B-Cell Lymphoma

Financial news for KPTI dated on 2017-06-07: Karyopharma Reports Dosing Of First Patient In Pivotal Phase 3 BOSTON Study Evaluating Selinexor In Patients With Relapsed/Refractory Multiple Myeloma

Financial news for KPTI dated on 2017-05-04: Karyopharm Therapeutics Q1 EPS \$(0.71) vs \$(0.67) Est, No Sales

Financial news for KPTI dated on 2017-05-03: Karyopharm and Anivive Lifesciences Sign Exclusive License Agreement For Verdinexor, Karyopharm To Receive \$1M Upfront Payment, Eligible to Receive Up To \$43.5M In Future Payments

Financial news for KPTI dated on 2017-04-25: Karyopharm Therapeutics Prices Offering of ~3.9M Shares at \$10.25/Share

Financial news for KPTI dated on 2017-04-24: Karyopharm Announces \$40M Offering Common Stock

Financial news for KPTI dated on 2017-04-04: Karyopharm Offers Interim Phase 2b SADAL Data (Selinexor): Achieved Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, 28.6% Overall Response Rate

Financial news for KPTI dated on 2017-04-04: Medidata, Karyopharm Report Expansion of Clinical Trial Partnership

Financial news for KPTI dated on 2017-04-03: Karyopharm Therapeutics Reports Stepping Down of CFO, Treasurer Justin Renz; Michael Todisco Named Interim Replacement

Financial news for KPTI dated on 2017-03-30: Karyopharm Therapeutics Reports FDA Division of Hematology Products Lifts Partial Clinical Hold on Selinexor Trials

Financial news for KPTI dated on 2017-03-16: Karyopharm Reports Q4 EPS \$(0.65) vs \$(0.66) Est.

Financial news for KPTI dated on 2017-03-13: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for KPTI dated on 2017-03-03: 15 Biggest Mid-Day Losers For Friday

Financial news for KPTI dated on 2017-03-03: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for KPTI dated on 2017-03-03: An Expected Failure From Karyopharm's Selinexor Doesn't Change The Bull Thesis

Financial news for KPTI dated on 2017-03-02: Karyopharm Shares to Resume Trade at 4:35 p.m. EST

Financial news for KPTI dated on 2017-03-02: Karyopharm Announces Phase 2 SOPRA Study Results, Selinexor Did Not Meet Primary Endpoint

Financial news for KPTI dated on 2017-03-02: Karyopharm Therapeutics Shares Halted News Pending

Financial news for KPTI dated on 2017-03-02: 25 Biggest Mid-Day Gainers For Thursday

Financial news for KPTI dated on 2017-02-16: Leerink Partners Global Healthcare Conference Concludes Today; Presenters Include Aurinia Pharmaceuticals, Karyopharm Therapeutics, Selecta Biosciences, TESARO, EXACT Sciences, Axovant Sciences, Achaogen

Financial news for KPTI dated on 2017-02-13: Key Presenters At Leerink's Healthcare Conference

Financial news for KPTI dated on 2017-02-07: Canaccord Genuity Rare Disease Biopharma One-On-One Day Takes Place Today; Presenters Include Aurinia Pharmaceuticals, Akari Therapeutics, Karyopharm, Selecta Biosciences, Aptose Biosciences, And Gemphire Therapeutics

Financial news for KPTI dated on 2017-02-06: Here's Your Sell-Side Conference Preview

Financial news for KPTI dated on 2016-12-09: Novan CEO Talks About The Company's Future: 'Our Focus Is Put On SB204'

Financial news for KPTI dated on 2016-12-07: Karyopharm Therapeutics CEO And CFO Talk Company Finances, Partnerships And Pipeline

Financial news for KPTI dated on 2016-12-06: Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia

Financial news for KPTI dated on 2016-12-05: Karyopharm Presents STOMP Phase 1b Data At ASH; STOMP Continues To Demonstrate High Response Rates In Combination With Bortezomib And Pomalidomide

Financial news for KPTI dated on 2016-12-05: American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena

Financial news for KPTI dated on 2016-12-05: Karyopharm Presents Updated Phase 2b STORM Data at ASH 2016

Financial news for KPTI dated on 2016-12-04: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at ASH 2016

Financial news for KPTI dated on 2016-12-02: American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4

Financial news for KPTI dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for KPTI dated on 2016-11-07: Karyopharm Reports Q3 Loss/Share \$0.69 vs Est Loss/Share \$0.81, Rev \$48K vs \$40K Est

Financial news for KPTI dated on 2016-10-11: Wellington Management Reports 11.83% Stake in Karyopharm Therapeutics in 13G

Financial news for KPTI dated on 2016-10-07: European Society For Medical Oncology Conference Commences Today (Oct.7 Thru Oct. 11)

Financial news for KPTI dated on 2016-10-05: Karyopharm Says 'Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers,' Will Present Updated SIGN Phase 2 Data at ESMO

Financial news for KPTI dated on 2016-10-04: Abstracts Expected Wednesday From Companies Presenting At The European Society For Medical Oncology Conf. Beginning Oct. 7th, Including From Karyopharm Therapeutics, Kite Pharma And Clovis Oncology

Financial news for KPTI dated on 2016-09-29: Karyopharm Reports Publishing of Preclinical Data Show Selinexor's Potential in KRAS-Mutant NSCLC

Financial news for KPTI dated on 2016-09-28: Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication

Financial news for KPTI dated on 2016-09-06: 10 Biggest Mid-Day Losers For Tuesday

Financial news for KPTI dated on 2016-09-06: Mid-Day Market Update: Navistar Rises After Strategic Alliance With Volkswagen Truck & Bus; Tonix Shares Drop

Financial news for KPTI dated on 2016-09-06: Wedbush Defending Karyopharma, Says Selinexor Displays Meaningful Activity In STORM, Maintains Outperform and \$14 PT

Financial news for KPTI dated on 2016-09-06: 10 Stocks Which Rallied Four Days, Then Sold Off On Friday

Financial news for KPTI dated on 2016-09-06: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KPTI dated on 2016-09-06: Karyopharm Reports 2b STORM Results Show Response Rates Of 20.8% In Quad-Refractory & 20% InPenta-Refractory Disease; Will Expand Study To Include 120 Patients With Penta-Refractory Myeloma To Support Accelerated Approval

Financial news for KPTI dated on 2016-09-06: Adam Feuerstein @adamfeuerstein Tweet: \$KPTI Penta-refractory multiple myeloma. That such a classification exists illustrates progress made in MM, but also competitive challenge.

Financial news for KPTI dated on 2016-08-30: Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ritchie Bros. Shares Spike Higher

Financial news for KPTI dated on 2016-08-30: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for KPTI dated on 2016-08-30: UPDATE: Karyopharm Therapeutics Sasy to Add ~120 Patients With Penta-Refractory MM

Financial news for KPTI dated on 2016-08-30: Karyopharm Therapeutics Says Intends To Expand Its Phase 2B Storm Study Evaluating Activity Of Selinexor In Multiple Myeloma

Financial news for KPTI dated on 2016-08-30: Mid-Day Market Update: Abercrombie & Fitch Drops On Wider Loss; Rigel Pharmaceuticals Shares Surge

Financial news for KPTI dated on 2016-08-30: Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations

Financial news for KPTI dated on 2016-08-30: Jefferies Upgrades Karyopharm To Buy As STORM Data Likely To Predict Sunny Skies

Financial news for KPTI dated on 2016-08-30: 5 Biggest Price Target Changes For Tuesday

Financial news for KPTI dated on 2016-08-30: Benzinga's Top Upgrades

Financial news for KPTI dated on 2016-08-30: Jefferies Upgrades Karyopharm Therapeutics to Buy, Raises PT to \$12.00

Financial news for KPTI dated on 2016-08-18: Benzinga's Top Initiations

Financial news for KPTI dated on 2016-08-18: H.C. Wainwright Initiates Coverage on Karyopharm Therapeutics at Buy, Announces \$15.00 PT

Financial news for KPTI dated on 2016-08-04: Karyopharm Reports Q2 EPS \$(0.84) vs \$(0.76) Est.

Financial news for KPTI dated on 2016-07-27: UPDATE: Karyopharm Reports Orphan Drug Designation for Selinexor

Financial news for KPTI dated on 2016-07-27: Karyopharm Reports Phase 1b Selinexor Sarcoma Data: is 'Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose'

Financial news for KPTI dated on 2016-06-28: Benzinga's Top Initiations

Financial news for KPTI dated on 2016-06-28: Baird Initiates Coverage on Karyopharm Therapeutics at Outperform

Financial news for KPTI dated on 2016-06-22: Karyopharm Commences First Stage Clinical Study With KPT-9274

Financial news for KPTI dated on 2016-06-22: Karyopharm Begins Phase 1 Clinical Trial with KPT-9274

Financial news for KPTI dated on 2016-06-16: Karyopharm Offers Outline for Key Selinexor Development Achievements: Enrollment Closed, Patient Dosing Underway in Phase 1b Trial

Financial news for KPTI dated on 2016-06-10: Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data, Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma

Financial news for KPTI dated on 2016-05-27: Benzinga's Top Initiations

Financial news for KPTI dated on 2016-05-27: Raymond James Initiates Coverage on Karyopharm Therapeutics at Outperform

Financial news for KPTI dated on 2016-05-27: Raymond James Initiates Coverage on Karyopharm Therapeutics at Outperform

Financial news for KPTI dated on 2016-05-09: Karyopharm Q1 EPS (\$0.75) vs (\$0.74) est

Financial news for KPTI dated on 2016-04-20: Karyopharm Offers Data Showing Potential of Nuclear XPO1 Inhibition in Treatment of Traumatic Brain Injury

Financial news for KPTI dated on 2016-03-31: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus

Financial news for KPTI dated on 2016-03-15: Bank of America Downgrades Karyopharm Therapeutics to Underperform, Lowers PT to \$11.00

Financial news for KPTI dated on 2016-03-14: JP Morgan Maintains Overweight on Karyopharm Therapeutics, Lowers PT to \$19.00, Believes Selinexor's Unique Mechanism Of Action Will Prove Useful In Several Oncology Indications

Financial news for KPTI dated on 2016-03-14: Karyopharm Therapeutics Reports Q4 EPS \$(0.81) vs \$(0.82) Est.

Financial news for KPTI dated on 2016-03-04: Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published in Journal of Clinical Oncology, Expects Phase 2/3 SCORE Study Initiation In Mid-2016

Financial news for KPTI dated on 2016-01-28: FDA Approves First Drug To Produce Evidence Of Survival Benefits in Lipsarcoma

Financial news for KPTI dated on 2016-01-14: Karyopharm Reports Initiation of Clinical Trial of Oral Selinexor in Advanced Liposarcoma; Phase 2/3 SEAL Trial Initiated

Financial news for KPTI dated on 2016-01-06: Jefferies Downgrades Karyopharm Therapeutics to Hold, Lowers to \$14.00

Financial news for KPTI dated on 2015-12-22: Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Steelcase Shares Dip Following Weak Results

Financial news for KPTI dated on 2015-12-22: Mid-Day Market Update: Cintas Gains On

Earnings Beat; NetApp Shares Slide

Financial news for KPTI dated on 2015-12-22: Mid-Morning Market Update: Markets Edge Higher; ConAgra Posts Mixed Q2 Results

Financial news for KPTI dated on 2015-12-07: Karyopharm Therapeutics Shows Positive Clinical Data on the Activity of Selinexor in Combination with Other Anticancer Agents across Multiple Hematologic Malignancies at the 2015 American Society of Hematology Meeting

Financial news for KPTI dated on 2015-11-30: Leerink Highlights Biotechs Poised To Benefit From ASH Conference

Financial news for KPTI dated on 2015-11-10: Amira Nature Foods, AlarmCom, Flotek Moving In Tuesday's After Hours Session

Financial news for KPTI dated on 2015-11-09: Karyopharm Reports Q3 EPS \$(0.85) vs \$(0.87) Est.

Financial news for KPTI dated on 2015-10-19: Karyopharm Initiates STOMP Clinical Trial of Oral Selinexor in Multiple Myeloma

Financial news for KPTI dated on 2015-09-09: Biotech Investors Still Have Opportunity

Financial news for KPTI dated on 2015-08-11: 4 More Biotechs Leerink Is Looking At Post-Earnings

Financial news for KPTI dated on 2015-08-10: Mid-Day Market Update: Dow Surges Over 200 Points; Dean Foods Shares Decline On Downbeat Sales

Financial news for KPTI dated on 2015-08-10: Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More

Financial news for KPTI dated on 2015-08-10: Mid-Morning Market Update: Markets Open Higher; Berkshire Hathaway To Acquire Precision Castparts For \$37.2B

Financial news for KPTI dated on 2015-08-10: Morning Market Losers

Financial news for KPTI dated on 2015-08-10: Karyopharm Reports Q2 EPS \$(0.92) vs. Est. \$(0.77)

Financial news for KPTI dated on 2015-07-17: Benzinga's Top Initiations

Financial news for KPTI dated on 2015-07-17: Bank of America Initiates Coverage on Karyopharm Therapeutics at Neutral, Announces \$32.00 PT

Financial news for KPTI dated on 2015-06-22: US Stock Futures Signal Higher Start On Wall Street

Financial news for KPTI dated on 2015-06-22: Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at International Conference on Malignant Lymphoma

Financial news for KPTI dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for KPTI dated on 2015-06-15: Leerink: Karyopharm Therapeutics Still A Buy, Cash Can Last Until 2018

Financial news for KPTI dated on 2015-06-15: Karyopharm Presents Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting

Financial news for KPTI dated on 2015-06-01: Karyopharma Says Selinexor Shows 38% Disease Control & 13% Overall Response Rate

Financial news for KPTI dated on 2015-05-30: Karyopharm Presents Positive Clinical Data for KPT-330 at ASCO

Financial news for KPTI dated on 2015-05-28: Karyopharm Begins STORM Clinical Trial of Oral Selinexor (KPT-330) in Multiple Myeloma

Financial news for KPTI dated on 2015-05-27: Karyopharm to Showcase Clinical Data Update for Selinexor (KPT-330) in Solid Tumors

Financial news for KPTI dated on 2015-05-21: US Stock Futures Edge Lower Ahead Of Economic Data

Financial news for KPTI dated on 2015-05-21: Karyopharm Announces Will Present Data

on Selinexor at EHA Annual Meeting on Jun 11-14

Financial news for KPTI dated on 2015-05-21: Karyopharm to Showcase Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting

Financial news for KPTI dated on 2015-05-12: Leerink Is Changing Targets At These 7 Biotechs

Financial news for KPTI dated on 2015-05-11: Karyopharm Reports Q1 Loss of \$0.74/Share vs Loss of \$0.75/Share Est.

Financial news for KPTI dated on 2015-04-21: Biotech Investors: May 29th Could Be A Big Day

Financial news for KPTI dated on 2015-04-13: Karyopharm Reports Granted US Composition-of-Matter Patent for Selinexor

Financial news for KPTI dated on 2015-03-20: 5 Biotech Stocks On JMP's Radar

Financial news for KPTI dated on 2015-03-16: Karyopharm Therapeutics Q4 EPS -\$0.79 Vs Est -\$0.69, Sales \$16K Vs \$40K

Financial news for KPTI dated on 2015-03-16: Earnings Scheduled For March 16, 2015

Financial news for KPTI dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for KPTI dated on 2015-02-24: Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks

Financial news for KPTI dated on 2015-02-23: Karyopharm Therapeutics Announces Nature Neuroscience Publishes Data Demonstrating Potential Therapeutic Benefits of Karyopharm's SINE(TM) In Multiple Sclerosis

Financial news for KPTI dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for KPTI dated on 2015-01-08: Karyopharm Reports Orphan Drug Designation Granted for Selinexor in Multiple Myeloma

Financial news for KPTI dated on 2015-01-07: Mid-Afternoon Market Update: Dow Jumps Over 200 Points After Fed Minutes; RPM Shares Drop On Downbeat Results

Financial news for KPTI dated on 2015-01-07: Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; Micron Shares Decline

Financial news for KPTI dated on 2015-01-07: 4 More Biotech Secondaries Investors Are Watching

Financial news for KPTI dated on 2015-01-07: Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops Estimates

Financial news for KPTI dated on 2015-01-07: Morning Market Losers

Financial news for KPTI dated on 2015-01-07: Wednesday Morning Movers

Financial news for KPTI dated on 2015-01-07: Karyopharm Therapeutics Prices 3M Share Offering @\$33.00/Share

Financial news for KPTI dated on 2015-01-06: 4 Biotech Secondary Offerings Traders Are Watching

Financial news for KPTI dated on 2015-01-05: From S-3: Karyopharm Therapeutics Files Automatic Mixed Shelf Offering

Financial news for KPTI dated on 2014-12-15: Karyopharm Announces Addition to the NASDAQ Biotechnology Index

Financial news for KPTI dated on 2014-12-11: Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher

Financial news for KPTI dated on 2014-12-11: Mid-Day Losers From December 11: RadioShack, Lee Enterprises, Karyopharm Therapeutics, Oxford Industries, Comtech

Financial news for KPTI dated on 2014-12-11: Karyopharm Initiates Third Registration-Directed Clinical Trial of Oral Selinexor

Financial news for KPTI dated on 2014-12-08: Karyopharm Presents Positive Clinical

Data For Selinexor In NHL Patients

Financial news for KPTI dated on 2014-12-08: Karyopharm Reports Positive Combo Data for Selinexor in MM Patients

Financial news for KPTI dated on 2014-12-01: Karyopharma Reports Added Orphan Designations Granted for KPT-330 by EC

Financial news for KPTI dated on 2014-11-24: Karyopharma Offers Data on Oncology Pipeline at EORTC-NCI-AACR Annual Meeting

Financial news for KPTI dated on 2014-11-10: Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation

Financial news for KPTI dated on 2014-11-10: Karyopharm Initiates Phase 2 Study of Selinexor in Patients With Richter's Transformation

Financial news for KPTI dated on 2014-11-10: Oppenheimer Upgrades Karyopharm Therapeutics to Outperform, Announces \$53.00 PT

Financial news for KPTI dated on 2014-11-04: Barrington Research Initiates Coverage on Karyopharm Therapeutics at Buy, Announces \$54.00 PT

Financial news for KPTI dated on 2014-10-27: Karyopharm Expands Global Presence With European Subsidiary

Financial news for KPTI dated on 2014-10-07: UPDATE: Webush Initiates Coverage On Karyopharm Therapeutics Inc On Selinexor Potential

Financial news for KPTI dated on 2014-10-06: Wedbush Initiates Coverage on Karyopharm Therapeutics at Outperform, Announces \$50.00 PT

Financial news for KPTI dated on 2014-09-29: Stocks Continue Lower On Merger Monday

Financial news for KPTI dated on 2014-09-29: Endologix Drops On Weak Forecast; TIBCO Software Shares Spike Higher

Financial news for KPTI dated on 2014-09-29: Midday Losers From September 29 - Tonix Pharmaceuticals Holding Corp., Digital Ally, Inc. And More

Financial news for KPTI dated on 2014-09-29: Markets Open Lower; Encana To Acquire Athlon Energy For \$5.93 Billion

Financial news for KPTI dated on 2014-09-29: Morning Market Losers

Financial news for KPTI dated on 2014-09-29: Karyopharm Reports Clinical Data for Selinexor in Advanced Solid Tumors

Financial news for KPTI dated on 2014-09-29: Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors

Financial news for KPTI dated on 2014-08-08: Karyopharm Announces Justin Renz CFO

Financial news for KPTI dated on 2014-08-07: Karyopharm Therapeutics Reports Q2 EPS of \$(0.55) vs \$(0.50) Est; Revenue of \$21.0M vs \$150.0K Est

Financial news for KPTI dated on 2014-07-08: Oppenheimer Initiates Coverage on Karyopharm Therapeutics at Market Perform

Financial news for KPTI dated on 2014-07-01: Karyopharm Therapeutics Shares Spike Lower

Financial news for KPTI dated on 2014-06-27: US Stock Futures Drop Ahead Of Consumer Sentiment Report

Financial news for KPTI dated on 2014-06-27: Karyopharm Therapeutics Prices 2.647M Share Offering at \$42.50/Share

Financial news for KPTI dated on 2014-06-25: Karyopharm Therapeutics Announces Offering of 2.2M Shares, 2M by Co., 200K Shares by Selling Holders

Financial news for KPTI dated on 2014-06-19: Karyopharm Therapeutics to Offer Up to \$115M in Stock

Financial news for KPTI dated on 2014-06-16: Mid-Afternoon Market Update: US Stocks Reverse Earlier Loses; Fusion-io Shares Jump On SanDisk Buyout

Financial news for KPTI dated on 2014-06-16: Mid-Day Market Movers For Monday, June

16, 2014

Financial news for KPTI dated on 2014-06-16: Mid-Day Market Update: US Stocks Turn Red; Fusion-IO Shares Jump On SanDisk Buyout

Financial news for KPTI dated on 2014-06-16: Mid-Morning Market Update: Markets Mostly Higher; Medtronic To Acquire Covidien For \$42.9B

Financial news for KPTI dated on 2014-06-16: Morning Market Losers

Financial news for KPTI dated on 2014-06-16: UPDATE: Karyopharma Announces FDA Sees Effectiveness, Safety for KPT-335

Financial news for KPTI dated on 2014-06-16: Karyopharma Announces FDA Sees Effectiveness, Safety for KPT-335

Financial news for KPTI dated on 2014-06-15: Veristat, Karyopharm Therapeutics Enter into Preferred Provider Agreement for Oncology and Novel Therapeutic Advancement

Financial news for KPTI dated on 2014-06-13: Karyopharm Reports First Combination Data of Selinexor With Low-Dose Dexamethasone in Heavily Pretreated Multiple Myeloma Patients

Financial news for KPTI dated on 2014-06-10: 13G Filing from Franklin Resources on Karyopharma Therapeutics Shows Increased Stake from 6.78% as of Mar. 31st to 11.9%

Financial news for KPTI dated on 2014-06-02: Karyopharm Offers Updates for Selinexor in Solid Tumors at ASCO 2014, Data Showed Continued Anti-Cancer Evidence

Financial news for KPTI dated on 2014-05-31: Karyopharm Reports Selinexor Shows Continued Evidence of Anti-Cancer Activity in NHL and AML at ASCO

Financial news for KPTI dated on 2014-05-20: Karyopharm Announces Second Orphan Drug Designation for Selinexor in Diffuse Large B-Cell Lymphoma (DLBCL)

Financial news for KPTI dated on 2014-05-19: Karyopharm Announces Drug for Acute Myeloid Leukemia Receives Orphan Drug Designation

Financial news for KPTI dated on 2014-05-16: FDA Announces Karyopharm's Selinexor Wins Orphan Drug Designation

Financial news for KPTI dated on 2014-05-07: Karyopharm Therapeutics Reports Q1 EPS of \$(0.46) vs \$(0.47) Est; Revenue of \$171.0M vs \$160.0K Est

Financial news for KPTI dated on 2014-04-29: Karyopharm Therapeutics Initiates Phase 2 Study of Selinexor

Financial news for KPTI dated on 2014-04-24: Karyopharm Initiates Phase 2 Study of Selinexor in Patients With Advanced Gynecologic Malignancies

Financial news for KPTI dated on 2014-04-22: Karyopharm Announces Five Clinical Data Presentations at ASCO

Financial news for KPTI dated on 2014-04-21: US Stock Futures Up Ahead Of Earnings

Financial news for KPTI dated on 2014-04-21: Karyopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Financial news for KPTI dated on 2014-04-15: Karyopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML)

Financial news for KPTI dated on 2014-04-10: Karyopharm Appoints Chris Primiano as General Counsel

Financial news for KPTI dated on 2014-04-10: Karyopharm Names Chris Primiano as General Counsel

Financial news for KPTI dated on 2014-04-09: Karyopharm Announces Entered Into Preferred Provider Deal with Clinipace Worldwide, No Terms Disclosed

Financial news for KPTI dated on 2014-03-24: Karyopharm Therapeutics Files for \$115M Offering of Common Stock

Financial news for KPTI dated on 2014-03-06: UPDATE: Bank of America Reiterates on Karyopharm Therapeutics on Significant Catalysts in 2014

Financial news for KPTI dated on 2014-03-06: Bank of America Maintains Buy on

Karyopharm Therapeutics, Raises PO to \$48.00

Financial news for KPTI dated on 2014-03-05: Adam Feuerstein Tweets: 'JMP's Mike King raised his WW sales estimate on \$KPTI lead drug selinexor to \$6.7B from \$3.4B based on PLANS for more ph2 studies.'

Financial news for KPTI dated on 2014-03-05: Karyopharm Therapeutics Reports 2013 Loss/Share \$5.59

Financial news for KPTI dated on 2014-01-22: Karyopharm Reports Data on Selinexor, Says Shows Anti-Tumor Activity

Financial news for KPTI dated on 2014-01-08: Karyopharm Reports Award of Grant from National MS Society to Further Develop SINE Compounds

Financial news for KPTI dated on 2013-12-08: Karyopharm Therapeutics Presents Promising Selinexor Data at ASH

Financial news for KPTI dated on 2013-12-02: UPDATE: Bank of America Initiates Coverage on Karyopharm Therapeutics on Novel Cancer Platform with Broad Potential

Financial news for KPTI dated on 2013-12-02: UPDATE: Oppenheimer Initiates Coverage on Karyopharm Therapeutics on Novel Mechanism with Broad Applicability in Oncology

Financial news for KPTI dated on 2013-12-02: JMP Securities Initiates Coverage on Karyopharm Therapeutics at Outperform, Announces \$25.00 PT

Financial news for KPTI dated on 2013-12-02: Bank of America Initiates Coverage on Karyopharm Therapeutics at Buy, Announces \$24.00 PO

Financial news for KPTI dated on 2013-12-02: Oppenheimer Initiates Coverage on Karyopharm Therapeutics at Outperform, Announces \$23.00 PT

Financial news for KPTI dated on 2013-11-06: IPO for Karyopharm Therapeutics Opens at \$17.86/Share After Pricing at \$16

Financial news for KPTI dated on 2013-11-06: Quotes for IPO of Karyopharm Therapeutics Now Available, Issue Expected to Open for Trade at 10:25AM EST